VP301

This bispecific antibody targets unique epitopes on CD38 and ICAM-1 on tumor cells with reduced red blood cell binding compared to the benchmark CD38 antibody daratumumab. Interestingly, combination of VP301 with the immunomodulatory drug, lenalidomide, led to synergistic anti-tumor growth activity in an in vivo efficacy study. In conclusion, the CD38 x ICAM-1 bispecific antibody VP301 demonstrated promising efficacy and specificity toward CD38+ and ICAM-1+ tumor cells and represents a novel approach for treating multiple myeloma and lymphoma.

Antibody against ICAM-1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody demonstrated potent tumor inhibition activities in in-vivo myeloma and lymphoma models. These studies suggested that CD38 x ICAM-1 bispecific antibody has multiple modes of action for treating lymphoma and multiple myeloma.

Antibody against ICAM1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody showed complete tumor inhibition in a rituximab-resistant lymphoma PDX model, whereas daratumumab only showed minimal efficacy. In conclusion, the CD38 x ICAM1 bispecific antibody demonstrated improved efficacy and specificity toward CD38 + and ICAM1 + tumor cells and represents a novel approach for treating multiple myeloma and lymphoma.